PALB2 and pancreatic neoplasm: NCT03140670 is a phase II trial of rucaparib evaluating patients with advanced pancreatic cancer with known germline or somatic BRCA or PALB2 mutations who had not progressed on at least 16 weeks of platinum treatment.